Document Detail

Group sequential extensions of a standard bioequivalence testing procedure.
MedLine Citation:
PMID:  8576845     Owner:  NLM     Status:  MEDLINE    
Bioequivalence trials compare the relative bioavailability of different formulations of a drug. Regulatory requirements for demonstrating average bioequivalence of two formulations generally include showing that a (say) 90% confidence interval for the ratio of expected pharmacologic end point values of the formulations lies between specified end points, e.g., 0.8-1.25. The likelihood of demonstrating bioequivalence when the formulations truly are equivalent depends on the sample size and on the variability of the pharmacologic end point. Group sequential bioequivalence testing provides a statistically valid way to accommodate misspecification of the variability in designing the trial by allowing for additional observations if a clear decision to accept or reject bioequivalence cannot be reached with the initial set of observations. This paper describes group sequential bioequivalence designs applicable in most practical situations that allow a decision to be reached with fewer observations than fixed-sample designs about 60% of the time at approximately the same average cost. The designs can be used in trials where the formulations are expected to have equal bioavailability and in trials where the formulations are expected to differ slightly. Data analyses are carried out exactly as for fixed-sample designs. Providing the capability of sequential decisions modestly affects the nominal significance levels, e.g., the required confidence level may be 93-94% instead of 90%.
A L Gould
Related Documents :
11228495 - Predicting outcomes of trials of labor in women attempting vaginal birth after cesarean...
15483415 - In silico design of clinical trials: a method coming of age.
18605475 - The prep statistic as a measure of confidence in model fitting.
10398975 - Stability, repeatability, and the expression of signal magnitude in functional magnetic...
19919685 - Exploring the black box of quality improvement collaboratives: modelling relations betw...
1645625 - Importance of experimental models for the development of clinical trials on thromboathe...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of pharmacokinetics and biopharmaceutics     Volume:  23     ISSN:  0090-466X     ISO Abbreviation:  J Pharmacokinet Biopharm     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1996-03-11     Completed Date:  1996-03-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0357115     Medline TA:  J Pharmacokinet Biopharm     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  57-86     Citation Subset:  IM    
Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Availability
Research Design
Sample Size
Therapeutic Equivalency*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Determination of protein binding by in vitro charcoal adsorption.
Next Document:  Fitting nonlinear regression models with correlated errors to individual pharmacodynamic data using ...